Novo Nordisk raises 2026 adjusted sales and operating profit outlook to 0% to -6% at constant exchange rates, driven by higher expected GLP-1 product sales, and records DKK6.3 billion non-cash impairment charges related to intangible pipeline assets in Q2.
FirstSquawk08/04, 11:41 PM
- 0% to -6% at CER
- DKK6.3 Bln
Figures as quoted by FirstSquawk